The BAX Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-mediated target-gene disruption product generated in the A-549 human lung adenocarcinoma epithelial cell line. This polyclonal knockout cell population is engineered to ablate BAX protein expression, delivering a robust loss-of-function model for interrogating the intrinsic apoptosis pathway. By eliminating a key pro-apoptotic effector, researchers can dissect BAX-dependent and -independent mechanisms governing cell death and survival. The cells are supplied as a cryopreserved pool, ready for immediate expansion in standard culture conditions.
The A-549 cell line, established from the lung adenocarcinoma of a 58-year-old Caucasian male, is a widely used adherent epithelial model for cancer biology and xenobiotic metabolism. These cells retain features of alveolar type II pneumocytes and exhibit wild-type p53 functionality, making them particularly relevant for studying DNA damage responses and apoptotic signaling. A-549 cells are extensively employed in drug discovery for evaluating chemosensitivity, metastasis, and signal transduction. Their integration into a BAX-null background provides a unique platform to explore apoptosis regulation within a clinically pertinent lung cancer context.
BAX is a central pro-apoptotic member of the BCL-2 family that promotes mitochondrial outer membrane permeabilization (MOMP), leading to cytochrome c release, APAF-1 apoptosome formation, and activation of caspase-9 and caspase-3. Transcriptionally regulated by p53 and E2F1, BAX is also activated post-translationally through interactions with BH3-only proteins such as BIM, PUMA, and NOXA. Its activity is counterbalanced by anti-apoptotic partners including BCL-2, BCL-XL, and MCL-1, and it cooperates with BAK to mediate mitochondrial dysfunction. In this knockout model, absence of BAX disrupts the intrinsic apoptosis pathway, conferring resistance to diverse stimuli including DNA-damaging agents, growth factor deprivation, and ER stress.
In the A-549 background, BAX knockout recapitulates an apoptosis-resistant phenotype commonly observed in chemoresistant lung adenocarcinomas. This model enables dissection of compensatory survival mechanisms and identification of BAX-independent death modalities. The polyclonal nature provides a broader representation of knockout genotypes compared to a single clone, reducing the risk of clone-specific artifacts. Researchers can use this system to evaluate the dependency of therapeutic candidates on BAX-mediated cell death, screen for synthetic lethal interactions, and study mitochondrial remodeling in the absence of a key executioner protein. The model is particularly powerful for assessing the efficacy of BH3 mimetics and other apoptosis-targeting agents in a BAX-deficient context.
This knockout product is suitable for a wide range of experimental readouts, including Western blot analysis of cleaved caspases and cytochrome c release, flow cytometric apoptosis assays (Annexin V/PI staining), cell viability determination (MTT, resazurin), caspase-3/7 activity luciferase assays, and mitochondrial membrane potential measurement using JC-1 dye. Additionally, colony formation assays and quantitative RT-PCR can be used to monitor long-term proliferative effects and transcriptional changes. Applications encompass drug sensitivity profiling (IC50 determination), testing of apoptosis-inducing compounds, and functional interrogation of BAX-related signaling networks in cancer and beyond. For further technical information, custom orders, or bulk pricing, please contact Ascent Research.
